CHARLOTTES WEB HLDGS (CWBHF) Stock News, May-Oct 2025

Charlotte's Web (OTCQB:CWBHF) launched Knockout, a blackberry-flavored hemp-derived THC + CBN sleep gummy, on October 14, 2025. Each 20-count bottle retails for $39.99 and is sold online and at select retailers nationwide.

Knockout uses the AZUCA TiME INFUSION™ delivery system for rapid onset (5–15 minutes), pairs THC to aid sleep onset with CBN to support uninterrupted rest, and is vegan, gluten-free, and made with U.S.-grown hemp.

Charlotte's Web (OTCQB: CWBHF) has launched Quiet Sleep Mushroom Gummies, expanding its sleep category with a melatonin-free and CBD-free sleep support solution. The new product combines organic reishi mushroom, chamomile flower extract, and magnesium citrate to promote relaxation and quality sleep.

The launch addresses a significant market need, as 43% of Americans report difficulty falling asleep due to racing minds. Available in strawberry lemon flavor, the gummies are priced at $34.99 for a 60-count bottle and will be available through the company's website starting September 30, 2025.

Charlotte's Web (OTCQB: CWBHF), a pioneer in hemp-derived CBD wellness, has announced plans to establish a Scientific Advisory Board in September 2025 to strengthen its medical channel strategy and accelerate R&D initiatives. The board will be led by Dr. Marcel Bonn-Miller, Chief Scientific Officer, a renowned cannabinoid researcher with over 20 years of experience.

The initiative aims to guide research and development, shape clinical initiatives, and create Continuing Medical Education (CME) content for healthcare professionals. This development reinforces the company's partnership with DeFloria, Inc. and Ajna BioSciences PBC, particularly in advancing AJA001, their FDA-approved Phase 2 clinical trial candidate for treating irritability associated with autism spectrum disorder.

Charlotte's Web (OTC:CWBHF) reported its Q2 2025 financial results, marking its second consecutive quarter of year-over-year growth. Revenue increased 4.2% to $12.8 million, while net loss improved to $6.3 million ($0.04 per share) from $11.0 million in Q2 2024.

The company achieved significant cost reductions, with SG&A expenses decreasing 31.7% year-over-year. Gross profit improved to $6.0 million (46.8% margin). Key operational highlights include the successful launch of Brightside™ THC gummies, expansion of botanical wellness portfolio, and implementation of in-house gummy production expected to generate $3 million in annualized cost savings.

Post-quarter initiatives are projected to reduce annualized costs by an additional $6 million in 2026. The company maintains a strong financial position with $15.3 million in cash and continues progress in FDA-cleared Phase 2 clinical trials for ASD treatment.

Charlotte's Web (TSX: CWEB, OTC: CWBHF), a leading CBD hemp extract wellness products company, has scheduled its 2025 second quarter earnings release and conference call for August 13, 2025. The financial results will be released before market open, followed by a conference call at 11:00 A.M. Eastern Time.

Investors can participate through multiple channels: automated callback registration, direct dial-in, or live webcast. The earnings call replay will be available until August 20, 2025, accessible via phone or through the company's investor relations website.

Charlotte's Web Holdings (CWBHF) held its 2025 annual general meeting on June 12, with shareholders casting 58,493,957 votes, representing 36.87% of total voting shares. The meeting focused on director elections, with all nominees securing positions. Maureen Usifer received the strongest support with 87% approval, while Matthew McCarthy and Angela McElwee each garnered 82% of votes. William Morachnick and Jonathan Atwood both received 72% support, and Jared Stanley secured his position with 66% of votes in favor.

DeFloria, in collaboration with AJNA BioSciences and Charlotte's Web (CWBHF), will participate in a key panel at the Benzinga Cannabis Capital Conference on June 9th, 2025, focusing on cannabis' transition from recreational to pharmaceutical applications. The panel, featuring industry leaders including Joel Stanley and Dr. Orrin Devinsky, will discuss DeFloria's groundbreaking AJA001 oral solution for autism spectrum disorder (ASD), which has received FDA clearance for Phase 2 clinical trials. The discussion will highlight the projected $1 trillion pharmaceutical cannabis market, DeFloria's first-mover advantage in botanical drug development, and their strategic positioning with Charlotte's Web's infrastructure. The company's AJA001 represents a paradigm shift by utilizing a multi-compound botanical approach rather than traditional single-molecule drugs, targeting a $50 billion global ASD therapeutic market.

Charlotte's Web (CWBHF) has announced the launch of Brightside™, a new line of precision-formulated, hemp-derived THC gummies. The product line features TiME INFUSION® rapid onset technology, delivering effects in 5-15 minutes, significantly faster than traditional edibles. The initial launch includes three variants: Rest & Relax, Focus & Flow, and Relieve & Ease, each containing micro-dosed THC combined with CBD, CBC, and CBG cannabinoids.

CEO Bill Morachnick will participate in the Benzinga Cannabis Capital Conference on June 10th, discussing industry sustainability in a panel titled "The Hemp Industry Divide: Quick Cash vs. Sustainable Growth." The launch aligns with growing consumer demand for low-dose THC edibles and targets health-conscious consumers seeking measured, intentional experiences.

Charlotte's Web (CWBHF) reported its first year-over-year revenue growth since 2021 in Q1 2025, with revenue reaching $12.3 million, up 1.1% from Q1 2024. The company's transformation strategy shows positive results through improved e-commerce performance and operational efficiencies. Key developments include: a nationwide rollout with Whole Foods Market starting June 2025, expansion into mushroom wellness products, and commencement of in-house gummy production. Financial highlights show reduced operating costs by 24.2% year-over-year, though gross margin decreased to 50.8%. The company maintains a strong cash position of $19.4 million. Additionally, DeFloria, their joint venture, received FDA clearance for Phase 2 clinical trials of AJA001 Oral Solution for autism spectrum disorder treatment.